I graduated in Biological Sciences (B.Sc, University of Salford, 1997) prior to undertaking a Ph.D in molecular microbiology studying quorum sensing in Pseudomonas aeruginosa (University of Nottingham, 2001). I worked as a Postdoctoral Fellow at Nottingham on both EU and BBSRC funded grants, before obtaining a Royal Society University Fellowship (2006-2014). I was promoted to Associate Professor in 2013. In 2017 I moved as an Associate Professor to the School of Biological Sciences at Georgia Tech. I was promoted to Full Professor in 2022. I was appointed as the Director of the Center for Microbial Dynamics and Infection in January 2023. 

I currently serve as the Deputy Editor in Chief of Microbiology, where I have previously served as editor and senior editor. I have also previously served on the editorial boards of FEMS Microbiology Letters, BMC Microbiology, Microbiology Open and Royal Society Open Science. I was an elected member of the Microbiology Society Council (2012-2016) and also served on their conference and policy committees. I was selected to be an American Society for Microbiology Distinguished Lecturer (2021-2023) and was elected to the American Academy of Microbiology in 2023. 

In my spare time I play bass guitar. I recorded some original music in a band called Meaner and I currently play in a covers band called The Variants of Concern. I also have a long-standing interest in the works of J.R.R. Tolkien.

Ingeborg Schmidt-Krey is an associate professor in the School of Biological Sciences at Georgia Tech. Her research interests lie in the structure and function of eukaryotic membrane proteins, two-dimensional crystallization, electron crystallography, single particle analysis, and electron cryo-microscopy (cryo-EM).

Dr. Jang’s lab uses multi-disciplinary approaches to study muscle stem cell biology and develops bioactive stem cell delivery vehicles for use in regenerative medicine. Dr. Jang’s lab studies both basic aspects of muscle stem cell biology, especially systemic/metabolic regulations of stem cell and stem cell niche, as well as more translational aspects of muscle stem cell and mesenchymal stem cell for use in therapeutic approaches for musculoskeletal aging, neuromuscular diseases, and traumatic injuries.

Terry Snell, an Emeritus Professor in the School of Biological Sciences, is a member of the Parker H. Petit Institute for Bioengineering and Bioscience.

My laboratory investigates molecular mechanisms underlying eukaryotic genome stability. Chromosomal rearrangements create genetic variation that can have deleterious or advantageous consequences. Karyotypic abnormalities are a hallmark of many tumors and hereditary diseases in humans. Chromosome rearrangements can also be a part of the programmed genetic modifications during cellular differentiation and development. In addition, gross DNA rearrangements play a major role in the chromosome evolution of eukaryotic organisms. Therefore, elucidation of molecular mechanisms leading to chromosome instability is important for studying human pathology and also for our understanding of the fundamental processes that determine the architecture and dynamics of eukaryotic genomes. 

My overall contribution to the field of genome instability has been the demonstration of the phenomenon that repeats often found in eukaryotic genomes are potent sources of genome instability. Specifically, I have been investigating one of the most fundamental and enigmatic processes as to how repetitive sequences that adopt non-canonical DNA secondary structures, such as hairpins and cruciforms, cause replication arrest, double-strand breaks, and gross chromosomal rearrangements. Using molecular biology approaches, we investigate the instability of secondary structure-forming repeats in Saccharomyces cerevisiae, Schizosaccharomyces pombe, and human fibroblasts.

Roman Mezencev's research uses genomics and functional genomics data, such as transcriptomics, methylomics, miRNA-omics, proteomics, and metabolomics, to identify distinct molecular subtypes of cancer and predict their sensitivity to traditional and new targeted anticancer agents. A more precise classification of cancer and the identification of new molecular subtypes can improve therapy decision-making and provide more accurate prognostication for cancer patients. 

In addition, he utilizes functional genomics to determine the potential of specific chemicals to cause cancer. Analyzing omics data also allows for identifying the carcinogenic mode of action of these chemicals and deriving their carcinogenic potency, which is crucial for human health risk assessment and public health considerations. 

Furthermore, cancer also has a unique molecular and epidemiological association with neurodegenerative diseases like Alzheimer's disease (AD), which is currently the seventh leading cause of death in the U.S. Mezencev's research explores these connections to identify shared risk factors and molecular mechanisms involved in the development of cancer and AD for a better understanding of these complex diseases and cross-pollination between anticancer and anti-AD drug development.

Roman Mezencev is an adjunct associate professor in the School of Biological Sciences at Georgia Tech and a scientist at the U.S. EPA’s National Center of Public Health and Environmental Assessment. His areas of research interest include cancer biology, pharmacology, toxicogenomics, protein misfolding diseases, and public health. In cancer biology, his main research focuses on using omics data to identify new cancer subtypes through molecular profiling, which can help enhance their diagnosis and treatment. Additionally, Mezencev explores the use of omics data to predict and understand chemically-induced cancer and other adverse outcomes to protect public health. He is also investigating the intriguing epidemiological associations and mechanistic connections between cancer and Alzheimer’s disease (AD), as well as other protein-misfolding diseases. By understanding these associations, we can identify shared risk factors and molecular mechanisms that can lead to the development of new anti-cancer and anti-AD drugs and enhance our understanding of these complex diseases.
 

King Jordan is Professor in the School of Biological Sciences and Director of the Bioinformatics Graduate Program at the Georgia Institute of Technology. He has a computational laboratory and his group works on a wide variety of research and development projects related to: (1) human clinical & population genomics, (2) computational genomics for public health, and (3) computational approaches to functional genomics. He is particularly interested in the relationship between human genetic ancestry and health. His lab is also actively engaged in capacity building efforts in genomics and bioinformatics in Latin America. 

Sam Brown's lab studies the multi-scale dynamics of infectious disease. Their goal is to improve the treatment and control of infectious diseases through a multi-scale understanding of microbial interactions. Their approach is highly interdisciplinary, combining theory and experiment, evolution, ecology and molecular microbiology in order to understand and control the multi-scale dynamics of bacteria pathogens.